Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 400,000,000
Countries
Sector(s)
Germany : € 400,000,000
Industry : € 400,000,000
Signature date(s)
14/12/2021 : € 400,000,000
Link to source

Summary sheet

Release date
22 December 2021
Status
Reference
Signed | 14/12/2021
20210113
Project name
Promoter - financial intermediary
PHARMA & MEDICAL DEVICES RDI PROGRAMME
FRESENIUS SE & CO KGAA
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 400 million
EUR 804 million
Location
Sector(s)
Description
Objectives

The project relates to the Promoter's expenditures in Research, Development and Innovation (RDI) in its portfolio of biosimilars, generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products.

The RDI activities focus on developing life-saving and affordable medicines and technologies for infusion, transfusion and clinical nutrition.

Additionality and Impact

The promoter is a European company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. In addition to its own RDI capabilities, it has developed a well-established network of collaborations with universities, research institutions and reputed industry partners. Companies producing innovative high-quality products are key drivers of economic growth, productivity and social protection, and generally a source of high value-added employment.


The project concerns a corporate R&D project of a company leading innovation within biosimilars, generics manufacturing, IV solutions, clinical nutrition, and medical devices. The promoter is a knowledge-based technological company focusing on developing medical devices for critical care and pharmaceuticals (biosimilars and generics) targeting unmet needs with high socio-economic impact such as oncology and autoimmune diseases. The company's R&D intensity is above sector average, which contributes positively towards the EU's 3% R&D intensity target. EIB's involvement will help to ensure that the important benefits of bringing its novel products entailed under this project to fruition in a timely manner despite the Covid-19 crisis. The products and services developed as a result of the project will improve the quality of life of patients suffering different severe and chronic conditions. Therefore the social value of the project is considered to be positive, over and above the financial return. EIB's contribution to the project stems from the combination of a financial advantage, flexible terms of the loan paired with convenient tenors, and helping to crowd-in other financiers, thereby facilitating its full financing and implementation.

Environmental aspects
Procurement

The RDI activities are expected to be carried out in existing facilities that are already used for the same purposes and that are not expected to change their scope due to the project. An Environmental Impact Assessment is therefore not needed as per EIA Directive 2014/52/EU amending Directive 2011/92/EU. The full environmental details will however be investigated by the Bank's services during the project due diligence.

The Promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the Promoter is subject to the EU public procurement legislation then the Bank would duly inform the Commission Services and would require the Promoter to apply those rules.

Link to source

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

Documents

Environmental and Social Data Sheet (ESDS) - PHARMA & MEDICAL DEVICES RDI PROGRAMME
Publication Date
3 Feb 2022
Document language
Main Topic
Lending
Document Number
139827764
Document Focus
Environmental Information
Project Number
20210113
Sector(s)
Regions
Countries
Publicly available
Download now

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications